The abstract of the publication detailing the results of the VITROCARD-0001 clinical study for VitroGro® ECM.
During the 2011-12 financial year, some of the most important final milestones necessary for the sales launch of VitroGro® ECM were successfully completed. Please download the report for details.
This publication highlights the requirements for an extracellular matrix (ECM) replacement therapy for the treatment of hard to heal wounds which compare favourably to the design and use of VitroGro® ECM.
Documents the high cost of Venous Leg Ulcers supporting the need for a cost effective treatment that can reduce the burden on the healthcare community.
Details the spiraling costs for treating hard to heal wounds and support the need for a product like VitroGro® ECM.